צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים: intracellulartherapies.com (ITCI)

Intra-Cellular Therapies (ITCI) is aggressively expanding its market presence driven by the commercial success of Caplyta in psychiatry. The TTM revenue growth trajectory compared to last year reflects demand dynamics, where 122.80 determines the current value of the metric. This growth is fueled by expansion into the bipolar disorder and depression segments, a drive for profitability, and the mitigation of patent risks through the diversification of its small-molecule drug portfolio.
Intra-Cellular Therapies Inc. (ITCI) - פילוחי מדדים ודוחות פיננסיים

This indicator calculates the percentage change in revenue over the last twelve months relative to the same period last year, capturing the actual speed of business expansion. Analyzing the LTM sales growth YoY allows for the determination of the market cycle phase, which is critical for Intra-Cellular Therapies (ITCI), as its revenues depend on neurological research with minimal expenditures on industrial infrastructure.